93 results about "Hypothalamus" patented technology

The invention discloses a traditional Chinese medicine compound oral preparation for treating male oligoasthenospermia, and belongs to the technical field of traditional Chinese medicine preparations. The rhizoma polygonati processed with wine, the prepared rehmannia root and the like are used for nourishing the liver and kidney to consolidate congenital, the codonopsis pilosula, the astragalus membranaceus and the like are used for invigorating spleen and replenishing qi to complement postnatal, the fried cowherb seed is used for activating blood circulation, and the salted semen plantaginis is used for promoting diuresis, so that the problems of insufficient spermatogenesis and low vitality caused by deficiency of the spleen and the kidney are fundamentally solved. Experiments and clinical researches show that the preparation can significantly improve the sperm quantity, activity and activity rate of oligoasthenospermia model mice and patients, the clinical total effective rate reaches 90%, the pregnancy rate reaches 53.3%, and the curative effect is superior to that of Wuzi Yanzong pills in a control group. The action mechanism covers regulation of blood lipid metabolism, improvement of hypothalamus-pituitary-gonad axis functions, repair of testicular seminiferous tubule structural damage and reduction of lipid deposition, and meanwhile, oxidative stress and inflammatory injury are relieved and spermatogenic cell functions are protected by regulating and controlling a PPAR signal channel and inhibiting molecular pathways such as Cga / Sting mediated cell apoptosis.

Compositions comprising microalgal extracellular vesicles (MEVs) formulated for intranasal delivery are provided, whereby upon intranasal administration, the MEVs are transported by a specific route, to specific regions in the brain via the olfactory nerve after intranasal administration, and to interconnected brain regions through the lateral olfactory tract (LOT). The MEVs are transported via neuronal axonal transport. The MEVs have the ability to cross synapses including: (i) synapses between olfactory sensory neurons (OSNs) and mitral / tufted neurons; (ii) synapses between mitral / tufted neurons and local neurons in multiple brain regions colonized by the lateral olfactory tract (LOT); and (iii) synapses between neurons in brain regions colonized by the LOT and neurons from the frontal cortex, hippocampus, thalamus, and hypothalamus. The compositions contain extracellular vesicles (MEVs) from microalgae loaded with bioactive cargo for the treatment, detection, diagnosis, or monitoring of diseases, disorders, or conditions of or involving the brain, particularly neuronal delivery of the cargo. The compositions and methods have multiple applications as therapeutic and diagnostic agents for the treatment, diagnosis, and monitoring of diseases, disorders, or conditions of or involving the brain. The compositions can be used in methods and uses for the treatment of cancers involving the brain, and can be used, for example, to deliver therapeutic agents for psychiatric diseases, disorders, conditions, and to deliver therapeutic agents for neurodegenerative diseases, disorders, and conditions.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention relates to the technical field of gene engineering, in particular to a kit for constructing a TBX19 p.Thr187Ala point mutation mouse model as well as a construction method and application of the kit. The kit provided by the invention comprises gRNA (guide ribonucleic acid) of which the nucleotide sequence is shown as SEQ ID NO.1 and single-stranded Oligo donor DNA (deoxyribonucleic acid) of which the nucleotide sequence is shown as SEQ ID NO.3. The invention also provides a kit for detecting the gRNA. According to the kit provided by the invention, a TBX19 p.Thr187Ala point mutation mouse model can be constructed, and the mouse model can be used as an animal model for studying the occurrence and development course of a hypothalamus-pituitary-adrenal axis function weakening and acrenocorticotropin (ACTH) deficiency model, so as to study the molecular and cellular mechanism of the TBX19 gene influencing animal (mouse) behaviors. The animal model can also be used as an animal model for research and development of adrenocorticotropin deficiency drugs.

The invention discloses a composition for regulating sleep rhythm homeostasis as well as a preparation method and application thereof. The composition for regulating the sleep rhythm homeostasis is prepared from the following components in percentage by weight: 5 to 18 percent of polydextrose, 9 to 15 percent of galactooligosaccharide, 1 to 10 percent of inulin, 0.4 to 2 percent of gamma-aminobutyric acid, 0.8 to 2.2 percent of L-theanine, 0.1 to 3.5 percent of magnesium citrate, 2 to 21 percent of semen ziziphi spinosae extract, 1 to 10 percent of poria cocos extract, 0.5 to 2 percent of pericarpium citri reticulatae extract, 0.3 to 1 percent of liquorice root extract and 15 to 40 percent of maltodextrin. 5-18% of coconut oil powder MCTs, and 0.5-2% of a lily extract. According to the application, a magnesium MCTs shell-core structure is delivered by maltodextrin to form a mitochondrial piezoelectric engine so as to improve prebiotics, promote flora metabolism efficiency and energy supply feedback, activate intestinal pheochromophilic cells and improve SLC6A4 gene expression so as to improve synthesis of 5-hydroxytryptamine in the brain and activate GABA energy neurons; meanwhile, through the spina date seed and poria cocos quantum dots and a pericarpium citri reticulatae and liquorice pi-pi stacking network, the blood-brain barrier penetration rate is greatly increased, and hypothalamic CRH release is adjusted.

The invention belongs to the field of biotechnology and nutritional medicine, relates to a maternal obesity intervention preparation, and particularly relates to a preparation method of a plant embryo fermentation product and application of the plant embryo fermentation product in blocking of trans-generation delivery metabolic diseases. FWG is prepared through a probiotic fermentation technology, obesity, glucose and lipid metabolism disorder and oxidative stress induced by high-fat diet of a parent body can be remarkably improved, and cross-generation transmission of metabolic diseases is blocked by adjusting composition of intestinal flora of the parent body and offspring and a hypothalamic PI3K-Akt signal channel. The invention reveals that maternal FWG intervention passes through a mechanism that a PI3K-Akt pathway is dominated and multiple pathways are coordinated on the transcriptome level for the first time, the HFD-induced offspring hypothalamus metabolism programming abnormality is reversed, and a new central regulation target is provided for cross-generation metabolic disease prevention. The FWG is a wheat processing byproduct, is free of chemical additives, is suitable for long-term dietary supplement, is a natural and safe nutrition intervention scheme, and is suitable for the field of maternal and infant health.

The invention provides lactobacillus plantarum for regulating mood health and resisting depression and application thereof, and the strain is separated from traditional pickles and is identified as lactobacillus plantarum. Experiments show that KY013 can significantly improve behavioral performance of depression model mice, and the effect of KY013 is equivalent to that of fluoxetine. The action mechanism comprises the following steps: up-regulating the levels of neurotransmitters such as 5-HT, DA, NE and GABA in hypothalamus, regulating the balance of proinflammatory factors (IL-6 and IFN-alpha) and anti-inflammatory factors (IL-10), and playing an anti-depression role through'neurotransmitter-immunity 'double ways. The KY013 disclosed by the invention can be used for developing antidepressant drugs or functional foods and the like, has the advantages of multi-target coordination, high safety and the like, and provides a new microecological preparation choice for treating depression.

The invention relates to application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for relieving depression or anxiety. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The invention develops a brand new application of the bifidobacterium animalis subsp. Lactis BLa80 strain, namely, the bifidobacterium animalis subsp. Lactis BLa80 strain is used for relieving depression or anxiety symptoms, specifically, the bifidobacterium animalis subsp. Lactis BLa80 strain can stimulate RIN14B cells to secrete 5-HT, can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety, can relieve hyperfunction of hypothalamic-pituitary-adrenal axis (HPA axis), and can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety. The inflammatory response of mice with depression and anxiety is relieved, the expression level of brain-derived neurotrophic factors in hippocampus of the mice with depression and anxiety is improved, the abundance of intestinal beneficial flora of the mice with depression and anxiety is improved, and the diversity of intestinal flora is increased.

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

The invention belongs to the field of traditional Chinese medicines, and provides application of a valerian extract in preparation of a medicine for preventing and treating climacteric syndrome. Pharmacological experiments show that the valerian extract has a regulation effect on a hypothalamic-pituitary-neuroendocrine system, and has important significance in regulating postmenopausal endocrine conditions of middle-aged and old women and improving anxiety, insomnia, dysphoria and other climacteric symptoms related to FSH (follicle stimulating hormone) and LH (luteinizing hormone). In addition, the valerian extract has a good regulation effect on secretion of related sex hormones and hypothalamus neurotransmitters of climacteric rats, and has a certain correction effect on the central monoamine neurotransmitter disorder state of the climacteric rats. The traditional Chinese medicine composition can improve clinical symptoms of climacteric syndrome.

The invention discloses a dynamic intelligent monitoring and early warning system based on endocrine gland functions, and relates to the technical field of endocrine monitoring, and the dynamic intelligent monitoring and early warning system comprises the following steps: obtaining hypothalamus, pituitary and target gland three-layer hormone concentration data, and carrying out timestamp alignment; after wavelet denoising, the deviation degree of each parameter relative to the health baseline is quantified; establishing an original differential equation set to simulate a hormone axis regulation and control relationship, and calculating a hierarchical weight; a fourth-order Runge-Kutta method is adopted to discretely solve a dynamic weight value; fusing the weight and the abnormality to generate a risk index, and dynamically adjusting an early warning line in combination with a hyperbolic threshold function; according to the threshold breakthrough duration and trend, three-level response of data review, targeted monitoring and drug intervention is triggered. According to the method, a hierarchical coupling differential equation is constructed by simulating a multi-stage regulation mechanism of an endocrine system, so that the recognition sensitivity of early signals of endocrine disorder is improved.

The present invention discloses the use of AZA1 in the preparation of a drug for treating sepsis and the drug itself, belonging to the field of biomedicine. AZA1 of the present invention can mediate hypothalamic microglial homeostasis through the Arhgap24-Rac1 / Cdc42 signaling axis, regulating the septic immune response, thereby promoting sepsis recovery and improving prognosis, providing a potential new strategy for central nervous system immune regulation in the treatment of patients with systemic sepsis.

A small molecule compound SPAM1 for up-regulating neuropeptide PACAP and receptor PAC1-R thereof, a method for preparing the same and use of the same; the SPAM1 has a structure of formula (I), wherein R=none, H2O or HCl; SPAM1 has small molecular weight, and can efficiently cross biological barriers including a blood-brain barrier, a blood-testis barrier etc; SPAM1 up-regulates the expression of the neurotransmitter / neuromodulator PACAP secreted by hypothalamus-pituitary and the specific receptor thereof, and acts on the glands downstream of the gonadal axis and the adrenal axis, thereby exerting comprehensive regulation effects; and SPAM1 specifically targets the PAC1-R1, and only acts on cells and tissues of nervous and endocrine systems naturally expressing the PAC1-R, thereby producing fewer side effects. Accordingly, SPAM1 is a novel small molecule compound medicament for effectively treating and preventing function decline and disorders of nervous, endocrine and immune systems closely related to neuropeptide PACAP.

The invention discloses application of AZA1 in preparation of a medicine for treating septicopyemia and the medicine, and belongs to the technical field of biological medicine. The AZA1 can mediate the homeostasis of the hypothalamic microglial cells through an Arhgap24-Rac1 / Cdc42 signal axis and regulate the septicopyemia immune response, so that the septicopyemia recovery is promoted, the prognosis is improved, and a potential new strategy for central nervous system immune regulation is provided for the treatment of whole-body septicopyemia patients.

The invention relates to a cerebroprotein peptide and casein hydrolysate composition and application thereof in improving sleep and memory, and belongs to the technical field of biological protein peptides. According to the preparation method disclosed by the invention, Maillard modification of the casein enzymolysis primary product is realized by screening the enzymolysis protease of the bovine milk casein and screening the carbonyl compound which is subjected to Maillard reaction with the casein enzymolysis primary product, so that the reducing power, the metal ion chelating capacity and the antioxidant capacity of the casein hydrolysate are effectively improved; furthermore, free radicals in the body are removed, oxidative stress reaction is relieved, and a good foundation is laid for improving sleep quality. The brain protein peptide and the casein hydrolysate are compounded, so that the sleep latency can be effectively shortened, the sleep rate can be increased, the sleep can be effectively improved, the content of dopamine and noradrenaline in hypothalamus can be reduced, the content of 5-hydroxytryptamine and the content of aminobutanoin can be increased, and the brain protein peptide composition has good effects of relieving and treating sleep disorders and improving memory.

This invention discloses a traditional Chinese medicine composition for improving hypertension, belonging to the field of traditional Chinese medicine compound preparation technology. This invention targets the core pathogenesis of hypertension caused by phlegm-dampness obstruction and peripheral microcirculation disorders, leading to abnormal activation of the hypothalamic-sympathetic-cardiac axis and compensatory cardiac hypertensive. The treatment principle is to resolve phlegm and dampness, and invigorate blood circulation. It is formulated with nutmeg, allium macrostemon, amomum villosum, peach kernel, safflower, platycodon grandiflorus, angelica dahurica, and tangerine peel. This combination can dredge the meridians, improve peripheral blood supply, and alleviate cardiac compensatory pumping, thus addressing hypertension caused by phlegm-dampness obstruction at its root. The formula is scientifically formulated, highly safe, and easy to prepare, making it suitable for long-term treatment and industrial promotion.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to an application of a ligusticum wallichii alcohol extract and an active monomer thereof in preparation of a product for relieving or treating food-borne obesity. Experimental research finds that when the ligusticum wallichii alcohol extract is singly used, the mRNA expression level of POMC in hypothalamus of a high-fat diet induced food-borne obesity mouse can be reduced, the alpha-MSH level in the hypothalamus can be improved, appetite can be effectively inhibited, body weight can be reduced, meanwhile, the number of lipid droplets in the liver can be reduced, and the ligusticum wallichii alcohol extract has the effects of relieving and treating food-borne obesity, preventing and treating hyperlipidemia and the like. And the application potential of liver tissues is improved, and a new direction and theoretical support are provided for treating food-borne obesity and expanding the medication range of ligusticum wallichii.

Combination therapies comprising oxytocin and gonadotropin releasing hormone are provided. The combinations can be used to treat aging-related neurological diseases or disorders. In addition, downstream effectors of OXT-GnRH combination, including hypothalamic stem / progenitor cells-derived EVs and vesicles containing or loaded with PTMS, can be used to treat aging-related neurological diseases or disorders.

The present application relates to the technical field of bioactive peptides, and in particular to an oat oligopeptide, preparation thereof and application thereof in preparing a product for regulating the expression of brain appetite suppressor factor. The oat oligopeptide can effectively stimulate the release of cholecystokinin (CCK) from intestinal endocrine cells, and stimulate the central nervous system through the vagus nerve pathway, thereby promoting the expression of the appetite suppressor factor pro-opiomelanocortin (POMC) in the hypothalamus. Compared with the prior art, the oat oligopeptide has the advantages of stable structure, high safety, simple preparation process (conventional enzymatic hydrolysis and chromatographic purification can achieve the preparation), easy scale production and the like. The oat oligopeptide is suitable for being used as a functional ingredient or a drug precursor to develop a related health product with the functions of regulating appetite and promoting satiety, and has a wide application prospect in the field of preparing functional products (food, medicine and the like).

To provide a gene construct for use in the treatment of a metabolic disorder in a mammal, particularly a human.SOLUTION: A gene construct provided comprising a nucleotide sequence encoding fibroblast growth factor 21 (FGF21) for use in the treatment and / or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS), preferably in the brain, more preferably in the hypothalamus and / or cortex and / or hippocampus and / or cerebellum and / or olfactory bulb, and most preferably in the hypothalamus.SELECTED DRAWING: None

The invention relates to an exosome for targeting a central nervous system delivery reagent. Protein for targeting the central nervous system on the exosome is one or more of membrane protein SIRP alpha, membrane protein MCAM and active fragments thereof. The exosome can efficiently target a central nervous system, can target a hippocampal region and a hypothalamic region, can deliver bioactive substances to the center and exert functions, and has good biocompatibility and biological safety.

The invention relates to the technical field of traditional Chinese medicines, relates to new application of a traditional Chinese medicine composition, and in particular relates to application of the traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating anxiety disorder. The traditional Chinese medicine composition is prepared from cassia twig, white peony root, honey-fried licorice root, ginger, jujube, ginseng, Chinese angelica, salted morinda officinalis and dwarf lilyturf tuber. The traditional Chinese medicine composition provided by the invention can obviously inhibit the anxiety state of an anxiety rat, reduce the contents of TNF-alpha, IL-1beta, IL-6, NE and 5-HT in serum of the anxiety rat, and increase the BDNF level; moreover, the content of IL-6, IL-1beta and TNF-alpha in hypothalamic tissues of anxiety rats can be reduced, and the compound has a relatively good treatment effect on anxiety.

The invention discloses an emotion memory generation system based on a memristor, and belongs to the field of integrated circuit design. The system comprises a brain emotion learning model and a hippocampus model. The brain emotion learning model comprises a thalamus module, a sensory cortex module, an orbital frontal cortex module and an amygdala kernel module; the hippocampus model comprises a DG module, a CA3 module and a CA1 module; under the stimulation of the emotional signals, the thalamus module firstly preprocesses the emotional signals, then the sensory cortex module and the orbital frontal lobe module integrate and process the preprocessed emotional signals, and the processed signals are respectively transmitted to the CA3 module and the amygdala kernel module to generate output signals representing emotions; under the stimulation of a learning signal, the DG module firstly preprocesses the learning signal, then the CA3 region is responsible for receiving the learning signal and generating an output signal representing short-term memory, and the output signal is transmitted to the CA1 region; and after receiving the short-term memory signal, the CA1 area converts short-term memory into long-term memory and stores the long-term memory.

The invention discloses Akkermansia muciniphila and application of a metabolite butyric acid of the Akkermansia muciniphila in preparation of drugs for relieving reproductive disorder of hypothalamus-pituitary-adrenal axis (HPA axis) and hypothalamus-pituitary-gonad axis (HPG axis), and develops a new function of the strain for relieving reproductive injury. The strain inhibits the HPA axis activity and reduces the stress hormone level by secreting butyric acid, so that the HPG axis function is activated, the reproductive system injury of ICR mice caused by high-density crowding stress is remarkably improved, and the sperm density is increased, the reproductive hormone level is increased, and the testis structure is improved. In addition, as a core metabolite of the Akkermansia muciniphila, the butyric acid can independently mediate the regulation and control process. The invention provides a new mechanism of animal population density-dependent reproductive homeostasis mediated by butyric acid, provides a potential micro-ecological intervention strategy for coping with reproductive capacity decline caused by social stress, and provides a new thought and method for treating animal and human reproductive injury.

The invention discloses a central obesity early warning method and system based on BDNF dynamic monitoring, and relates to the field of dynamic monitoring of brain-derived neurotrophic factors.The method comprises the steps that the weight, the body length, the body temperature and the food intake of an experimental subject are obtained, fasting blood glucose and blood fat are detected through caudal vein blood sampling, a standardized physiological index data set is formed, and the standard physiological index data set is stored in a database; the method comprises the following steps: carrying out anatomical sampling on hypothalamus tissues, scapular brown adipose and perirenal adipose, and carrying out Western Blot detection to obtain the BDNF expression quantity of the hypothalamus tissues, the BDNF expression quantity of the scapular brown adipose tissues and the BDNF expression quantity of the perirenal adipose tissues; and acquiring the BDNF concentration time sequence data of the hypothalamus extracellular fluid through the implanted microdialysis module. According to the method, dynamic continuous monitoring of hypothalamic BDNF secretion is achieved through the implanted microdialysis technology, the rhythm disorder degree is quantified by calculating the sample entropy value, the limitation of a traditional static detection method is broken through, and early metabolic regulation abnormity can be captured more sensitively.

The invention belongs to the technical field of probiotic and amino acid compositions, and particularly relates to a compound probiotic composition as well as a preparation method and application thereof. The compound probiotic composition is prepared from the liposome, the compound probiotics, the compound amino acid, the vitamin and the complexing agent, the liposome serves as a carrier, the 12 probiotics, the compound amino acid and the vitamin serve as active ingredients, the complexing agent enables the active ingredients and the carrier to be fully fused and bonded, and therefore the compound probiotic composition is prepared by utilizing the carrier property and the fusion property of the liposome. And the wrapped active components can safely pass through the stomach and are absorbed by the intestinal tract, so that the effective components can be quickly absorbed and utilized. The compound probiotic composition prepared by the invention not only has the effects of protecting brain nerves, soothing nerves and promoting sleep, but also can effectively repair tissues such as amygdala kernel, hippocampus, hypothalamus and pineal body, nourish nerves and help to stabilize emotion.

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclosure describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.

This invention discloses a traditional Chinese medicine composition for assisting in the improvement of hand-foot-mouth disease in infants and young children, belonging to the field of traditional Chinese medicine technology. The composition consists of eight medicinal herbs: lotus leaf, coix seed, angelica dahurica, kudzu root, platycodon root, agastache rugosa, cimicifuga rhizome, and dandelion, with a defined optimal medicinal ratio. Based on the seasonal differences in the pathogenesis of hand-foot-mouth disease, this invention targets the core pathologies of winter (cold congestion of microvessels, water and sodium retention, and internal heat generation) and spring and summer (hypothalamic sympathetic activation, increased heart rate, and visceral heat overload). It also addresses the technical deficiencies of clinical Western medicine, cold-natured traditional Chinese medicine, calamine lotion, and diuretics, such as vasoconstriction, kidney damage, central nervous system disorders, increased skin exudation, and rebound water retention. This invention employs a combination of warming and cooling herbs, regulating the ascending and descending functions, and promoting diuresis and protecting the body's vital energy. The synergistic effects of these herbs can dilate spasmodic microvessels, improve renal perfusion, stabilize abnormal heart rates, stabilize the hypothalamic center, and assist in antagonizing enteroviruses. By targeting and reducing abnormal permeability of skin capillaries with Angelica dahurica and Platycodon grandiflorus, it reduces blood extravasation and inhibits the formation and exudation of herpes from the root cause. This invention has mild medicinal properties, is suitable for all seasons, and has high safety. It can effectively improve symptoms of hand-foot-mouth disease such as fever, herpes, irritability, and cold extremities, reduce the risk of severe illness, antagonize the toxic side effects of commonly used clinical drugs, and is suitable for the delicate constitution of infants and young children, possessing good prospects for clinical application and promotion.

The invention relates to the technical field of monoclonal antibody preparation and immunological detection, in particular to a reagent or a kit for detecting E2 through an antibody sandwich method and application of the reagent or the kit. The paired monoclonal antibody has strong specificity and high detection sensitivity, and solves the problems of low content of E2 in human serum and high detection difficulty. The monoclonal antibody is applied to a magnetic particle estradiol content detection kit. The kit is used for detecting the E2 content in serum, is combined with other sex hormone index detection and clinical manifestation, is beneficial to diagnosis of sex hormone disorder diseases, and has clinical significance in detection of diseases such as fertility disorders in thalamus-pituitary-gonad axis, male mammary gland development, estrogenic ovarian and testicular tumors, adrenal cortex hyperplasia and the like.